Claro Advisors’s GSK GSK Stock Holding History

Claro Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,010	Closed	-$101K	–	479
2018 Q4	$101K	Buy	+2,010	New	+$99K	0.08%	227

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Claro Advisors's GSK Position: Q1 2019 in Review

Claro Advisors sold out of GSK (GSK) in Q1 2019, closing a stake of 2,010 shares — an estimated $101K sold.

Claro Advisors first reported a position in GSK in Q4 2018 and held it in 1 quarter. The position peaked at $101K in Q4 2018. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Claro Advisors reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 2,010 GSK shares in Q1 2019, an estimated $101K.
Claro Advisors first reported a position in GSK in Q4 2018 and held it in 1 quarter.
Claro Advisors's GSK position peaked at $101K in Q4 2018.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.